<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916370</url>
  </required_header>
  <id_info>
    <org_study_id>06-373</org_study_id>
    <nct_id>NCT00916370</nct_id>
  </id_info>
  <brief_title>SPIRIT PRIME Clinical Trial</brief_title>
  <acronym>SPIRIT PRIME</acronym>
  <official_title>SPIRIT PRIME Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion
      (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter
      in subjects with symptomatic heart disease due to a maximum of two de novo native coronary
      artery lesions, each in a different epicardial vessel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>From insertion to withdrawal of guide catheter</time_frame>
    <description>Procedure time is defined as time between insertion and withdrawal of guide catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success (Lesion Basis)</measure>
    <time_frame>From the start of index procedure to end of index procedure</time_frame>
    <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt; 50% (by QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success (Subject Basis)</measure>
    <time_frame>From the start of index procedure to end of index procedure</time_frame>
    <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA). Per Protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>In-hospital is less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure.</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>30 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>180 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>1 year</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>2 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</measure>
    <time_frame>3 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>30 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>180 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>1 year</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>2 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel MI (Q-wave, Non Q-wave)</measure>
    <time_frame>3 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated-Target Lesion Revascularization</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TLR (CI and Non-CI)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All TVR (CI and Non-CI)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (TVR and Non-TVR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI</measure>
    <time_frame>30 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>180 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>in-hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>30 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>180 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>1 year</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>2 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/ All MI/CI-TLR</measure>
    <time_frame>3 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>180 days</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Coronary Revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Per Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Acute (≤1 day)</time_frame>
    <description>Per protocol and per Academic Research Consortium (ARC, definite/probable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Subacute (&gt;1 - 30 days)</time_frame>
    <description>Per protocol and per ARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Acute/Subacute (0 - 30 days)</time_frame>
    <description>Per protocol and per ARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Late (31 - 393 days)</time_frame>
    <description>Per protocol and per ARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Late (31 - 758 days)</time_frame>
    <description>Per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Very Late (394 - 758 days)</time_frame>
    <description>Per ARC, definite and probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Late (31 - 1123 days)</time_frame>
    <description>Per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Very Late (394 - 1123 days)</time_frame>
    <description>Per ARC, definite and probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Overall (0-393 days)</time_frame>
    <description>Per protocol and per ARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Overall (0-758 days)</time_frame>
    <description>Per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Overall (0-758 days)</time_frame>
    <description>Per ARC, definite and probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Overall (0 - 1123 days)</time_frame>
    <description>Per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Overall (0 - 1123 days)</time_frame>
    <description>Per ARC, definite and probable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">525</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Core size registry (CSR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Core size indicates the range of diameters of the stents used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long lesion registry (LLR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of long lesion stents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Core size Xience Prime</intervention_name>
    <description>Core size includes a range of stent sizes.</description>
    <arm_group_label>Core size registry (CSR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience Prime Long Lesion (LL)</intervention_name>
    <description>Long lesion stent sizes include a range of sizes.</description>
    <arm_group_label>Long lesion registry (LLR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 18 years of age.

          2. Subject or a legally authorized representative must provide written informed consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or a reversible change in the
             electrocardiogram (ECG) consistent with ischemia).

          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          5. Subject must agree to undergo all protocol-required follow-up procedures.

          6. Subject must agree not to participate in any other clinical study for a period of one
             year following the index procedure.

        Angiographic Inclusion Criteria

          1. One or two de novo target lesions each in a different epicardial vessel.

          2. If there are two target lesions, both lesions must satisfy the angiographic
             eligibility criteria for that registry.

             o Multiple focal de novo lesions in a target vessel that can be covered by a single
             stent are allowed.

          3. The target lesion(s) must be located in a major artery or branch with a visually
             estimated diameter stenosis of ≥ 50% and &lt; 100% with a TIMI flow of ≥ 1.

          4. Target lesion(s) must be located in a native coronary artery with reference vessel
             diameter (RVD) by visual estimation of:

               -  ≥ 2.25 mm and ≤ 4.25 mm for treatment by the core size XIENCE PRIME EECS

               -  ≥ 2.5 mm and ≤ 4.25 mm for treatment by the XIENCE PRIME LL EECS

          5. Target lesion(s) must be located in a native coronary artery with length by visual
             estimation of:

               -  ≤ 22 mm for treatment by the core size XIENCE PRIME EECS

               -  &gt; 22 mm and ≤ 32 mm for treatment by the XIENCE PRIME LL EECS

        Exclusion Criteria:

          1. Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the
             index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not
             returned to within normal limits at the time of procedure.

          2. The subject is currently experiencing clinical symptoms consistent with new onset AMI,
             such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.

          3. Subject has current unstable cardiac arrhythmias associated with hemodynamic
             instability.

          4. Subject has a known left ventricular ejection fraction (LVEF) &lt; 30% (LVEF may be
             obtained at the time of the index procedure if the value is unknown and if necessary).

          5. Subject has received coronary brachytherapy in any epicardial vessel (target or non
             target).

          6. Subject has received any organ transplant or is on a waiting list for any organ
             transplant.

          7. Subject is receiving or scheduled to receive chemotherapy for malignancy within 30
             days prior to or within one year after the index procedure.

          8. Subject is receiving or scheduled to receive planned radiotherapy to the
             chest/mediastinum.

          9. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus
             etc.).

         10. Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).

         11. Subject will require Low Molecular Weight Heparin (LMWH) post-procedure.

         12. Subject has a known hypersensitivity or contraindication to aspirin,
             heparin/bivalirudin, clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel,
             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be
             adequately pre-medicated.

         13. Elective surgery is planned within 12 months after the procedure that will require
             discontinuing either aspirin or clopidogrel.

         14. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a white blood
             cell (WBC) of &lt; 3,000 cells/mm3, or documented or suspected liver disease (including
             laboratory evidence of hepatitis).

         15. Subject has known renal insufficiency (examples being but not limited to estimated
             glomerular filtration rate (eGFR) &lt; 60 ml/kg/m2, serum creatinine level ≥ 2.5 mg/dL,
             or on dialysis).

         16. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

         17. Subject has had a cerebrovascular accident/stroke or transient ischemic neurological
             attack (TIA) within the past six months.

         18. Subject has had a significant gastro-intestinal or significant urinary bleed within
             the past six months.

         19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion.

         20. Subject has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the protocol, confound the data interpretation or is associated
             with a limited life expectancy (i.e., less than one year).

         21. Subject is currently participating in another clinical study that has not yet
             completed its primary endpoint.

         22. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test.

        Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual
        estimation.

          1. Target lesion located within an arterial or saphenous vein graft or distal to a
             diseased (vessel irregularity per angiogram and &gt; 20% stenosed lesion) arterial or
             saphenous vein graft.

          2. Target lesion involving a bifurcation with a side branch ≥ 2 mm in diameter and/or
             ostial lesion &gt; 40% stenosed or side branch requiring protection guide wire, or side
             branch requiring dilatation.

          3. Target lesion with total occlusion (TIMI flow 0), prior to crossing with the wire.

          4. Another lesion requiring revascularization is located in the same epicardial vessel of
             the target lesion.

          5. Restenotic target lesion.

          6. Aorto-ostial target lesion (within 3 mm of the aorta junction).

          7. Target lesion is in a left main location.

          8. Target lesion located within 2 mm of the origin of the LAD or LCX.

          9. Extreme angulation (≥ 90 °) or excessive tortuosity (≥ two 45° angles) proximal to or
             within the lesion.

         10. Heavy calcification proximal to or within the target lesion.

         11. Target vessel contains thrombus as indicated in the angiographic images.

         12. Target lesion has a high probability that a procedure other than pre-dilatation and
             stenting will be required at the time of index procedure for treatment of the target
             vessel (e.g. atherectomy, cutting balloon).

         13. Target vessel is previously treated with any type of PCI (e.g. balloon angioplasty,
             stent, cutting balloon, atherectomy) &lt; 9 months prior to index procedure.

         14. Non-target vessel is previously treated with any type of PCI &lt; 90 days prior to the
             index procedure.

         15. Additional clinically significant lesion(s) (e.g. %DS ≥ 50%) in a target vessel or
             side branch for which PCI may be required &lt; 90 days after the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Costa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Hospital</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital of Pensicola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504-8721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center P.C.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Health System, Pierremont</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Hospital</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health System</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gotham Cardiology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMH Regional Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health @ Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Texas Healthcare System</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlake Hospital Medical Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Clinics Northwest/ Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4061</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Heart</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2012</results_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Restenosis</keyword>
  <keyword>Long lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled into this trial will be male and female subjects from the general interventional cardiology population. The study commenced on June 5, 2009 with the first subject enrolled on June 15, 2009. The last subject in the CSR was enrolled February 12, 2010, and the last subject enrolled in LLR was on April 6, 2010.</recruitment_details>
      <pre_assignment_details>Intention-to-treat (ITT) set includes 525 subjects: 415 in core size registry (CSR) arm and 110 in long lesion registry (LLR) arm. Full analysis set (FAS) (n=505, 401 in CSR arm and 104 in LLR arm) includes subjects who have received at least 1 of the following: the core size XIENCE PRIME or XIENCE PRIME LL stent system, including bailout.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Core Size Registry</title>
          <description>Core size indicates the range of diameters of the stents used.</description>
        </group>
        <group group_id="P2">
          <title>Long Lesion Registry</title>
          <description>Use of long lesion stents.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics data is presented for FAS population (n=505) for this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Core Size Registry</title>
          <description>Core size indicates the range of diameters of the stents used.</description>
        </group>
        <group group_id="B2">
          <title>Long Lesion Registry</title>
          <description>Use of long lesion stents.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="401"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="505"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.70" spread="10.23"/>
                    <measurement group_id="B2" value="63.46" spread="9.44"/>
                    <measurement group_id="B3" value="62.86" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>Procedure time is defined as time between insertion and withdrawal of guide catheter.</description>
        <time_frame>From insertion to withdrawal of guide catheter</time_frame>
        <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Therefore, the final analysis contained 403 ITT CSR subjects and 106 ITT LLR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Procedure time is defined as time between insertion and withdrawal of guide catheter.</description>
          <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Therefore, the final analysis contained 403 ITT CSR subjects and 106 ITT LLR subjects.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="21.1"/>
                    <measurement group_id="O2" value="46.9" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success (Lesion Basis)</title>
        <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt; 50% (by QCA).</description>
        <time_frame>From the start of index procedure to end of index procedure</time_frame>
        <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Therefore, the final analysis contained 403 ITT CSR subjects and 106 ITT LLR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success (Lesion Basis)</title>
          <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt; 50% (by QCA).</description>
          <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Therefore, the final analysis contained 403 ITT CSR subjects and 106 ITT LLR subjects.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success (Subject Basis)</title>
        <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA). Per Protocol.</description>
        <time_frame>From the start of index procedure to end of index procedure</time_frame>
        <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Out of these subjects, 2 in the CSR and 1 in the LLR did not have QCA data and therefore were excluded. So, the final analysis contained 401 ITT CSR subjects and 105 ITT LLR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success (Subject Basis)</title>
          <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt; 50% (by QCA). Per Protocol.</description>
          <population>The analysis was done to include only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge). Out of these subjects, 2 in the CSR and 1 in the LLR did not have QCA data and therefore were excluded. So, the final analysis contained 401 ITT CSR subjects and 105 ITT LLR subjects.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>In-hospital is less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure.</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
        <description>Per Protocol</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel-Myocardial Infarction (TV-MI) - Q-wave and Non Q-wave (Defined as MI Not Clearly Attributable to a Non-target Vessel)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
        <description>Per Protocol</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel MI (Q-wave, Non Q-wave)</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated-Target Lesion Revascularization</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated-Target Lesion Revascularization</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Indicated Target Vessel Revascularization (TVR = TLR and Non-TLR in TV)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TLR (CI and Non-CI)</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TLR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All TVR (CI and Non-CI)</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All TVR (CI and Non-CI)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (TVR and Non-TVR)</title>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Coronary Revascularization (TVR and Non-TVR)</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI</title>
        <description>Per Protocol</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <description>Per Protocol</description>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <description>Per Protocol</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <description>Per Protocol</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <description>Per Protocol</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <time_frame>in-hospital</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <description>Per Protocol</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <description>Per Protocol</description>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <description>Per Protocol</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <description>Per Protocol</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/ All MI/CI-TLR</title>
        <description>Per Protocol</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/ All MI/CI-TLR</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>In-hospital is defined as hospitalization less than or equal to 7 days post index procedure</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>180 days</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Coronary Revascularization</title>
        <description>Per Protocol</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI/All Coronary Revascularization</title>
          <description>Per Protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol and per Academic Research Consortium (ARC, definite/probable)</description>
        <time_frame>Acute (≤1 day)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol and per Academic Research Consortium (ARC, definite/probable)</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per ARC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol and per ARC</description>
        <time_frame>Subacute (&gt;1 - 30 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol and per ARC</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per ARC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol and per ARC</description>
        <time_frame>Acute/Subacute (0 - 30 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol and per ARC</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per ARC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol and per ARC</description>
        <time_frame>Late (31 - 393 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol and per ARC</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per ARC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol</description>
        <time_frame>Late (31 - 758 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per ARC, definite and probable</description>
        <time_frame>Very Late (394 - 758 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per ARC, definite and probable</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol</description>
        <time_frame>Late (31 - 1123 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per ARC, definite and probable</description>
        <time_frame>Very Late (394 - 1123 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per ARC, definite and probable</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
        <time_frame>2 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
        <time_frame>3 years</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>Use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>The composite rate of:
Cardiac Death Target Vessel Myocardial Infarction (TV-MI) and Clinically Indicated Target Lesion Revascularization (CI-TLR) per protocol.</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol and per ARC</description>
        <time_frame>Overall (0-393 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol and per ARC</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Per ARC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol</description>
        <time_frame>Overall (0-758 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per ARC, definite and probable</description>
        <time_frame>Overall (0-758 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per ARC, definite and probable</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per protocol</description>
        <time_frame>Overall (0 - 1123 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per protocol</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>Per ARC, definite and probable</description>
        <time_frame>Overall (0 - 1123 days)</time_frame>
        <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Core Size Registry</title>
            <description>Core size indicates the range of diameters of the stents used.</description>
          </group>
          <group group_id="O2">
            <title>Long Lesion Registry</title>
            <description>use of long lesion stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Thrombosis</title>
          <description>Per ARC, definite and probable</description>
          <population>The number of participants analyzed is based on FAS population, defined as subjects who have received the investigational study device and excludes subjects who are truly lost-to-follow-up, defined as subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>These are site-reported, un-adjudicated adverse events regardless of relationship to the device in intention-to-treat population. The number of participants at risk excludes subjects who were early terminated up to 1123 days and had no events through the given timepoint</desc>
      <group_list>
        <group group_id="E1">
          <title>Core Size Registry</title>
          <description>Core size indicates the range of diameters of the stents used.</description>
        </group>
        <group group_id="E2">
          <title>Long Lesion Registry</title>
          <description>Use of long lesion stents.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="83" subjects_affected="59" subjects_at_risk="412"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Microvascular angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Barretts oesophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pharyngoesophageal diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Other injuries</sub_title>
                <description>Other injuries consists of all the Preferred Terms (PT) which were not in Administration site reactions and Procedural and device related injuries and classifications High-Level Group Terms category for the corresponding System Organ Class (SOC)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pedal pulse decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Other renal and urinary disorders</sub_title>
                <description>Other renal and urinary disorders consist of all the PTs which were not in Acute renal failure for the corresponding SOC.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Wegeners granulomatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Scrotal haematocoele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="114" subjects_affected="89" subjects_at_risk="412"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="412"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="412"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="77" subjects_affected="71" subjects_at_risk="412"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication except to delay any proposed publication or presentation to enable the Sponsor to secure patent or other protection of proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Smith Jr, Ph.D., Sr Clinical Research Scientist</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-8265</phone>
      <email>robert.smithjr@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

